Skip to main content
Nikhil Khushalani, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

NikhilIshwarKhushalaniMD

Oncology • Tampa, FL

Hematologic Oncology, Melanoma

Senior Member (Tenured), Moffitt Cancer Center

Request Appointment

Overview of Dr. Khushalani

Dr. Nikhil Khushalani is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Topiwala National Medical College and has been in practice 22 years. Dr. Khushalani accepts several types of health insurance, listed below. He is one of 172 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • University at Buffalo
    University at BuffaloFellowship, Hematology and Medical Oncology, 1999 - 2002
  • University at Buffalo
    University at BuffaloResidency, Internal Medicine, 1996 - 1999
  • Topiwala National Medical College
    Topiwala National Medical CollegeClass of 1995

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2015 - 2026
  • NY State Medical License
    NY State Medical License 2006 - 2016
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain  
    Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
  • PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma  
    Jade Homsi, Michael R Migden, Nikhil I Khushalani, The New England Journal of Medicine
  • Malignant Adnexal Tumors of the Skin: A Single Institution Experience  
    Valerie Francescutti, Kilian Salerno, John 3rd Kane, Tolutope Oyasiji, Joseph Skitzki, Nikhil I Khushalani, BioMed Central

Lectures

  • CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously un... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Melanoma 2013: Standard Treatment, Novel Therapies, and Ongoing Controversies 
    Cvent Online Event Registration Software, Amherst, New York - 4/13/2013
  • 13th Annual Radiation Oncology Conference for Therapists & Dosimetrists 
    Roswell Park Cancer Institute, Niagara Falls, New York - 9/6/2012

Press Mentions

  • Moffitt's 'Mole Patrol' Offers Free Skin Cancer Screenings
    Moffitt's 'Mole Patrol' Offers Free Skin Cancer ScreeningsMay 1st, 2022
  • Rationale for Combining a Modified IL-2 and Nivolumab in Melanoma
    Rationale for Combining a Modified IL-2 and Nivolumab in MelanomaJuly 8th, 2019
  • Immunotherapy Combo Fails Melanoma Test
    Immunotherapy Combo Fails Melanoma TestJune 26th, 2019
  • Join now to see all

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem Blue Access PPO
    Anthem Blue Preferred HMO
    BCBS Blue Card PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    First Health PPO
    GHI PPO
    Great West PPO
    HealthAmerica HealthAssurance PPO
    HIP of New York - Select PPO
    Humana ChoiceCare Network PPO
    MagnaCare PPO
    Medical Mutual of Ohio SuperMed Plus
    Medical Mutual of Ohio SuperMed POS
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare HMO
    MVP Healthcare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Nikhil Khushalani, Dr. Nikhil Khushalani, MD, Dr. N Khushalani, Dr. Nikhil Ishwar Khushalani